News
Issued by Pierre Fabre Pharmaceuticals Inc., not Atara Biotherapeutics, Inc.
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
November 3, 2025 · View original source (PR Newswire)
It isn’t one of Atara Biotherapeutics, Inc.’s news releases, so 6ix doesn’t show it on Atara Biotherapeutics, Inc.’s page or send it as an alert.